Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

Takaaki Ono, Masayuki Hino, Itaru Matsumura, Shin Fujisawa, Kenichi Ishizawa, Emiko Sakaida, Naohiro Sekiguchi, Chiho Ono, Mana Aizawa, Yusuke Tanetsugu, Yuichiro Koide, Naoto Takahashi

Blood (2021) 138 (Supplement 1): 2557.

https://doi.org/10.1182/blood-2021-145164

Published: 2021

Journal Articles

A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML)

Naoto Takahashi, MD, PhD, Kenichi Ishizawa, MD, Chiaki Nakaseko, M.D., Ph.D., Yukio Kobayashi, MD, PhD, Kazuteru Ohashi, MD, FACP, Yasunori Nakagawa, MD, Kazuhito Yamamoto, M.D., Ph.D., Koichi Miyamura, MD, PhD, Masafumi Taniwaki, MD, PhD, Masaya Okada, MD, PhD, Tatsuya Kawaguchi, MD, PhD, Atsushi Shibata, BE, Yosuke Fujii, PhD, Chiho Ono, PhD, Kazunori Ohnishi, MD, PhD

Blood (2013) 122 (21): 2736.

https://doi.org/10.1182/blood.V122.21.2736.2736

Published: 2013

Journal Articles

Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Kiyohiko Hatake, MD, PhD, Michinori Ogura, MD, PhD, Kiyoshi Ando, MD, PhD, Kota Tokushige, Chiho Ono, PhD, Erik R. Vandendries, MD, PhD, Kensei Tobinai, MD, PhD

Blood (2010) 116 (21): 2872.

https://doi.org/10.1182/blood.V116.21.2872.2872

Published: 2010

Journal Articles

Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC- 544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab.

Kensei Tobinai, MD, PhD, Michinori Ogura, MD, PhD, Kiyohiko Hatake, MD, PhD, Yukio Kobayashi, MD, PhD, Takashi Watanabe, MD, PhD, Toshiki Uchida, MD, PhD, Masanobu Kasai, MD, Masahiro Yokoyama, MD, Yasuhito Terui, MD, PhD, Chiho Ono, Masanao Akiyama, Junko Ohata, MD, PhD

Blood (2008) 112 (11): 1565.

https://doi.org/10.1182/blood.V112.11.1565.1565

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML)

Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC- 544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab.

Email alerts

ASH Publications

American Society of Hematology

Update search

Efficacy and Safety of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: Final 3-Year Results of a Phase 2 Study

A Phase 1/2 Study Of Bosutinib (SKI-606) In Japanese Adults With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML)

Phase 1 Study of Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Japanese Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Phase I and Pharmacokinetic Study of Inotuzumab Ozogamicin (CMC- 544) as a Single Agent in Japanese Patients with Follicular Lymphoma Pretreated with Rituximab.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only